ATE170185T1 - Kristaliner polymorph von terazosin und dies enthaltende pharmazeutische zusammensetzungen - Google Patents

Kristaliner polymorph von terazosin und dies enthaltende pharmazeutische zusammensetzungen

Info

Publication number
ATE170185T1
ATE170185T1 AT96307027T AT96307027T ATE170185T1 AT E170185 T1 ATE170185 T1 AT E170185T1 AT 96307027 T AT96307027 T AT 96307027T AT 96307027 T AT96307027 T AT 96307027T AT E170185 T1 ATE170185 T1 AT E170185T1
Authority
AT
Austria
Prior art keywords
crystalline polymorph
terazosine
pharmaceutical compositions
compositions containing
containing same
Prior art date
Application number
AT96307027T
Other languages
English (en)
Inventor
Mahendra R Patel
Kasireddy Chandraprakash Reddy
Pankaj J Dave
Original Assignee
Invamed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invamed Inc filed Critical Invamed Inc
Application granted granted Critical
Publication of ATE170185T1 publication Critical patent/ATE170185T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT96307027T 1995-10-24 1996-09-26 Kristaliner polymorph von terazosin und dies enthaltende pharmazeutische zusammensetzungen ATE170185T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/547,209 US5587377A (en) 1995-10-24 1995-10-24 Terazosin crystalline polymorph and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
ATE170185T1 true ATE170185T1 (de) 1998-09-15

Family

ID=24183758

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96307027T ATE170185T1 (de) 1995-10-24 1996-09-26 Kristaliner polymorph von terazosin und dies enthaltende pharmazeutische zusammensetzungen

Country Status (5)

Country Link
US (1) US5587377A (de)
EP (1) EP0770612B1 (de)
JP (1) JPH09124644A (de)
AT (1) ATE170185T1 (de)
DE (1) DE69600565T2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19546573A1 (de) * 1995-12-13 1997-06-19 Uetikon Chemie Gmbh Kristallines Polymorph von Terazosin-Hydrochlorid, sowie Verfahren zu seiner Herstellung
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
IT1286790B1 (it) * 1996-11-29 1998-07-17 Alfa Chem Ital Processo per la produzione della forma i del terazosin monocloridrato anidro
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
US6248888B1 (en) 1997-11-14 2001-06-19 Teva Pharmaceutical Industries Ltd. Process for the preparation of terazosin hydrochloride dihydrate
US7521793B2 (en) * 2005-09-26 2009-04-21 Temic Automotive Of North America, Inc. Integrated circuit mounting for thermal stress relief useable in a multi-chip module
US11224572B1 (en) 2020-08-17 2022-01-18 Novitium Pharma LLC Stable oral liquid composition of terazosin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
ATE72244T1 (de) * 1986-03-21 1992-02-15 Heumann Pharma Gmbh & Co Kristalline, wasserfreie sigma -form von 2-(4-(2furoyl-(2-piperazin)-1-yl>-4-amino-6,7- dimethoxychinazolinhydrochlorid und verfahren zu ihrer herstellung.
US5212176A (en) * 1990-06-29 1993-05-18 Abbott Laboratories R(+)-terazosin
JP2652272B2 (ja) * 1990-12-31 1997-09-10 住化ファインケム株式会社 １−（４−アミノ−６，７−ジメトキシ−２−キナゾリニル）−４−（２−テトラヒドロフロイル）ピペラジン塩酸塩の新規な結晶体および該結晶体の製造方法
US5294615A (en) * 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition
US5412095A (en) * 1993-04-29 1995-05-02 Abbott Laboratories Terazosin monohydrochloride and processes and intermediate for its production
US5504207A (en) * 1994-10-18 1996-04-02 Abbott Laboratories Process and intermediate for the preparation of terazosin hydrochloride dihydrate

Also Published As

Publication number Publication date
DE69600565T2 (de) 1999-05-12
US5587377A (en) 1996-12-24
EP0770612B1 (de) 1998-08-26
EP0770612A1 (de) 1997-05-02
DE69600565D1 (de) 1998-10-01
JPH09124644A (ja) 1997-05-13

Similar Documents

Publication Publication Date Title
CA2216796A1 (en) Quinazoline derivatives
PT831837E (pt) Utilizacao de esqualamina no fabrico de um medicamento para inibicao de nhe
HU9602489D0 (en) New piperazine derivatives, process for producing them and pharmaceutical compositions containing them
HUP9802839A3 (en) Quinazoline derivatives, pharmaceutical compositions containing them and process for producing them
HUP9801692A3 (en) Benzimidazole compounds, pharmaceutical compositions containing them and their use for producing pharmaceutical compositions
GEP20043163B (en) Inhibitors of Caspases, Pharmaceutical Composition on its Base and Method for its Production
ATE249435T1 (de) Neue kristalline form gamma des tert-butylamin salzes von perindopril, verfahren zu deren herstellung und dieses enthaltende arzneimittel
MA26516A1 (fr) Tartrate d'un dipeptide substitue, procede pour sa preparation et compositions pharmaceutiques le contenant.
EP0680328A1 (de) Topisches ketoconazoles arzneimittel.
YU44895A (sh) Višejedinični dozni oblici u tabletama koji sadrže omeprazol i jednu njegovu alkalnu so ili jedan enantiomer omeprazola ili jednu njegovu alkalnu so
EE9600019A (et) 2,8-diasendatud kinasolinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
DE60045528D1 (de) Pharmazeutische zusammensetzungen, die ccr5-antagonisierende piperazinderivate enthalten
HUP9802259A3 (en) 1,4,5-substituted imidazole compounds, pharmaceutical compounds containing them, process for producing them and their use
HUP9602601A3 (en) Piperidine and piperazine derivatives, medicines containing them as active ingredient and their use
MXPA05005895A (es) Composicion farmaceutica de 1-(3, 4-dimetoxifenil)-4 -metil-5-etil -7-metoxi-8 -hidroxi- 5h-2, 3-benzodiacepina y usos de la misma.
EE9600030A (et) N-(3-bensofuranüül)karbamiidderivaadid, nende valmistamismeetod, kasutamine ravimite valmistamiseks, nimetatud ühendeid sisaldavad ravimid ja nende valmistamismeetod
ATE170185T1 (de) Kristaliner polymorph von terazosin und dies enthaltende pharmazeutische zusammensetzungen
PL329027A1 (en) Derivatives of benzopyrane exhibiting antagonistic activity in respect to leucotriene
DE69500380D1 (de) Zusammensetzung, die einen Precursor von Dihydroxyaceton enthaelt
HUP9800512A3 (en) Salts of bismuthum and antibiotica of the moenomycin group, process for producing them, their use and pharmaceutical compositions containing them
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
CA2174707A1 (en) Chromone derivatives as nk1 and substance p antagonists
ES8506291A1 (es) Procedimiento para la preparacion de 4-amino-6, 7-dimetoxi-2-(4-(furo-2-il)-piperazin-1-il)-quinazolina y sus sales fisiologicamente aceptables
HUP9801789A3 (en) Sulfonamide substituted compounds, process for producing them, their use for producing pharmaceutical compositions and pharmaceutical compositions containing said compounds
FI964429A7 (fi) Menetelmä 1-(3-trialkyylisilyylifenyyli)-2,2,2-trifluorimetyylietanoni n johdannaisten valmistamiseksi